Editing of the human genome to correct disease-causing mutations is a promising approach for the treatment of genetic disorders. Genome editing improves on simple gene-replacement strategies by effecting in situ correction of a mutant gene, thus restoring normal gene function under the control of endogenous regulatory elements and reducing risks associated with random insertion into the genome. Gene-specific targeting has historically been limited to mouse embryonic stem cells. The development of zinc finger nucleases (ZFNs) has permitted efficient genome editing in transformed and primary cells that were previously thought to be intractable to such genetic manipulation 1 . In vitro, ZFNs have been shown to promote efficient genome editing via homology-directed repair by inducing a site-specific double-strand break (DSB) at a target locus [2] [3] [4] , but it is unclear whether ZFNs can induce DSBs and stimulate genome editing at a clinically meaningful level in vivo. Here we show that ZFNs are able to induce DSBs efficiently when delivered directly to mouse liver and that, when co-delivered with an appropriately designed gene-targeting vector, they can stimulate gene replacement through both homology-directed and homologyindependent targeted gene insertion at the ZFN-specified locus. The level of gene targeting achieved was sufficient to correct the prolonged clotting times in a mouse model of haemophilia B, and remained persistent after induced liver regeneration. Thus, ZFNdriven gene correction can be achieved in vivo, raising the possibility of genome editing as a viable strategy for the treatment of genetic disease.
Viral-vector-mediated transfer of the wild-type copy of a gene that is defective in disease (gene replacement therapy) has been performed successfully in a variety of animal models and in humans [5] [6] [7] [8] [9] . However, disadvantages of gene replacement include risks related to insertional mutagenesis [10] [11] [12] and loss of endogenous regulatory signals that control gene expression. Gene-specific targeting in mouse induced pluripotent stem cells has highlighted the potential to overcome these challenges through ex vivo correction of a disease-causing mutation 13 . However, most genetic diseases affect organ systems in which ex vivo manipulation of target cells is not feasible. One such organ is the liver, the major site of synthesis of plasma proteins, including blood coagulation factors. A model genetic disease for gene therapy in the liver is haemophilia B, which is caused by deficiency of blood coagulation factor IX, encoded by the F9 gene. Most affected individuals have circulating levels of factor IX that are below 1% of normal (5,000 ng ml 21 ), but restoration to about 5% activity (250 ng ml 21 ) converts severe haemophilia B to a mild form 14 . Most mutations in the F9 gene are distributed across the coding sequences of exons 2-8 ( Fig. 1a) 15 . Thus, specific targeting of any single mutant allele would not allow complete coverage of the wide spectrum of mutations found in the human population. However, ZFN-mediated targeting of a promoterless therapeutic gene fragment 2, 16 (that is, a partial cDNA preceded by a splice acceptor site) into the first intron of F9 would allow for splicing of a wild-type coding sequence with exon 1, leading to expression of functionally active factor IX and rescue of the defect caused by most mutations. We therefore sought to investigate whether ZFNs combined with a targeting vector carrying the wild-type F9 exons 2-8 could induce gene targeting in vivo and correct a mutated F9 gene in situ.
We designed ZFNs targeting intron 1 of the human F9 (hF9) gene (F9 ZFNs, Supplementary Fig. 1 ) and confirmed their capacity to introduce a DSB at the intended target site ( Fig. 1b ) and to stimulate genome editing by homology-directed repair (HDR) in human erythroleukaemia K-562 cells ( Fig. 1c, d active, driving small insertions and/or deletions (indels), characteristic of DSB repair by non-homologous end-joining (NHEJ), in up to 45% of alleles, and stable integration of the NheI restriction site in ,17-18% of alleles. This latter event is diagnostic of repair by HDR, using a homologous donor template designed to insert a novel restriction enzyme site into the F9 locus. Similar results were obtained in the Hep3B human hepatocyte line ( Supplementary Fig. 2 ). For in vivo evaluation, we generated a humanized mouse model of haemophilia B because the F9 ZFNs target a site in intron 1 of hF9 that is absent from the murine gene. We constructed an hF9 mini-gene 17 , under the control of a liver-specific enhancer and promoter 18 , that mimics a previously identified mutation (Y155stop) 19 , resulting in the absence of circulating factor IX protein. We knocked in this mini-gene at the mouse ROSA26 locus 20 , confirmed its genotype ( Fig. 2a ) and showed that the resulting transgenic mice had no detectable circulating human factor IX ( Fig. 2b ). We then crossed these mice (hereafter referred to as hF9mut mice) with an existing mouse model that has a deletion of the murine F9 gene 21 , generating hF9mut/HB mice to test ZFN-driven gene correction activity in vivo ( Fig. 3a) .
To deliver the F9 ZFNs to the liver, we generated a hepatotropic adeno-associated virus vector, serotype 8 (AAV8-ZFN) expressing the F9 ZFNs from a liver-specific enhancer and promoter 18 . To test the cleavage activity of the F9 ZFNs in vivo, we injected hF9mut mice through the tail vein with AAV8-ZFN and isolated liver DNA at day 7 after injection. Cleavage activity was measured via the surveyor nuclease 
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(Cel-I) assay 22 which determines the frequency of indels that are characteristic of DSB repair by NHEJ. We observed mutation frequencies ranging from 34% to 47%, demonstrating that coupling of the F9 ZFNs with AAV8-mediated delivery promotes highly efficient genome modification in mouse liver ( Fig. 2c ). These results were confirmed by direct sequencing of the target locus ( Supplementary Fig. 3 ).
To correct the mutated hF9 gene in situ, we generated an AAV donor template vector (AAV8-donor) for gene targeting, with arms of homology flanking a corrective, partial cDNA cassette containing exons 2-8 of the wild-type hF9 gene, flanked by splice-acceptor and poly-adenylation sites (Fig. 3a) . Having established that we could detect HDR readily in vitro ( Supplementary Fig. 4 ), we co-injected hF9mut/ HB mice by intraperitoneal injection at day 2 of life with AAV8-ZFN 1 AAV8-donor, AAV8-mock 1 AAV8-donor or AAV8-ZFN alone. (Note that intraperitoneal injection in neonatal mice is less efficient than tail-vein injection in adult mice (compare Cel-I results in Fig. 3b to those in Fig. 2c ) but it is used because it leads to higher survival rates.) At week 10 of life, we extracted liver DNA to assay gene replacement at the hF9 locus via HDR. Using primers that hybridize to the chromosome outside the donor homology arms, generating a larger amplicon for a targeted allele ( Fig. 3a , primers P1/P3 and Fig. 3b , upper panel), we observed HDR only in mice receiving both the donor and F9 ZFNs, with targeting efficiencies in the 1-3% range (Fig. 3b , upper panel). We confirmed HDR using alternative primers that hybridize to sites outside the donor homology arms and within the inserted cassette, respectively ( Fig. 3a , primers P1/P2 and Fig. 3b , middle panel). Thus, co-delivery of ZFNs and a donor template, using AAV vectors, leads to HDR in vivo.
To determine whether ZFN-mediated gene targeting results in production of circulating human factor IX, we injected hF9mut mice intraperitoneally at day 2 of life with AAV8-ZFN alone, AAV8mock 1 AAV8-donor or AAV8-ZFN 1 AAV8-donor. Human factor IX levels in the plasma of mice receiving ZFN alone or mock 1 donor averaged ,15 ng ml 21 (the lower limit of detection of the assay), whereas mice receiving ZFN 1 donor averaged 116-121 ng ml 21 , corresponding to 2-3% of normal levels ( Fig. 4a ): significantly more than mice receiving ZFN alone and mice receiving mock 1 donor (P # 0.006 at all time points, 2-tailed t-test, Supplementary Fig. 5 ). Notably, in individual mice, the amount of circulating human factor IX correlated directly with the detected level of gene targeting via HDR ( Supplementary Fig. 6 ).
To confirm stable genomic correction, we performed partial hepatectomies. Levels of human factor IX persisted after hepatectomies performed after genome editing ( Fig. 4a ), whereas an episomal AAV vector expressing human factor IX (AAV-human factor IX, Fig. 4b ) showed markedly reduced human factor IX expression after hepatectomy, because extra-chromosomal episomes are lost during liver regeneration 23 (Fig. 4b ). Control mice receiving ZFN alone or mock 1 donor continued to average ,15 ng ml 21 after hepatectomy ( Fig. 4a ) (P # 0.01 at all time points, 2-tailed t-test, Supplementary Fig. 5 ).
To ensure that the expression of human factor IX did not result from random donor integration into the genome, we injected wild-type mice (lacking the hF9mut mini-gene) intraperitoneally at day 2 of life with AAV8-ZFN alone, AAV8-mock 1 AAV8-donor or AAV8-ZFN 1 AAV8-donor. Notably, human factor IX levels in the plasma of mice in these groups averaged ,15 ng ml 21 , ,30 ng ml 21 and ,30 ng ml 21 , respectively ( Fig. 4c) , indicating that most of the expression of human factor IX in hF9mut mice treated with ZFN 1 donor came from specific gene correction. PCR targeting assays in these wild-type control mice were negative, indicating that amplicons used to quantify HDR were target-gene-specific ( Supplementary Fig. 7) .
To determine whether ZFN-mediated gene targeting would provide circulating levels of human factor IX that were sufficient to correct the haemophilia B phenotype, we injected hF9mut/HB mice intraperitoneally at day 2 of life with AAV8-ZFN alone, AAV8-mock 1 AAV8donor or AAV8-ZFN 1 AAV8-donor. Levels of human factor IX in the plasma of mice receiving ZFN alone again averaged ,15 ng ml 21 . Mice receiving mock 1 donor averaged ,25 ng ml 21 and mice receiving ZFN 1 donor had significantly higher levels of human factor IX (P # 0.04 at all time points compared to mock 1 donor, 2-tailed t-test, Supplementary Fig. 5 ), averaging 166-354 ng ml 21 , 3-7% of normal circulating levels (Fig. 5a) . A titration of AAV-donor showed that the IX. a, Levels of human factor IX in plasma of hF9mut mice after intraperitoneal injection at day 2 of life with either 5 3 10 10 v.g. AAV8-ZFN alone (n 5 7), 5 3 10 10 v.g. AAV8-ZFN and 2.5 3 10 11 v.g. AAV8-donor (n 5 7), or 5 3 10 10 v.g. AAV8-mock and 2.5 3 10 11 v.g. AAV8-donor (n 5 6). Partial hepatectomy (PHx) was performed at the time indicated by the arrow. Plasma levels of human factor IX were assayed by ELISA. Error bars denote s.e.m. b, Levels of human factor IX in plasma of wild-type mice (n 5 3) after tail-vein injection of 1 3 10 9 v.g. AAV-human-factor-IX (predominantly episomal), with subsequent PHx. Plasma levels of human factor IX were assayed by ELISA. Error bars denote s.e.m. c, Levels of human factor IX in plasma of wild-type C57BL/6J mice after intraperitoneal injection at day 2 of life with either 5 3 10 10 v.g. AAV8-ZFN alone (n 5 8 before PHx, n 5 4 after PHx), 5 3 10 10 v.g. AAV8-ZFN and 2.5 3 10 11 v.g. AAV8-donor (n 5 9 before PHx, n 5 5 after PHx), or 5 3 10 10 v.g. AAV8-mock and 2.5 3 10 11 v.g. AAV8-donor (n 5 6 before PHx, n 5 5 after PHx). Plasma levels of human factor IX were assayed by ELISA. Error bars denote s.e.m.
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degree of correction was dependent on the dose of AAV-donor ( Supplementary Fig. 8 ). To determine whether the haemophilia B phenotype was corrected, we assayed activated partial thromboplastin time (aPTT), a measure of clot-formation kinetics that is markedly prolonged in haemophilia. The average aPTTs for wild-type mice (n 5 5) and haemophilia B mice (n 5 12) were 36 s and 67 s, respectively ( Fig. 5b) . Mice receiving mock 1 donor (n 5 3) averaged 60 s, whereas mice receiving ZFN 1 donor (n 5 5) had significantly shortened aPTTs, averaging 44 s (P 5 0.0014 compared to mock 1 donor, 2-tailed t-test). Clotting times for ZFN 1 donor and wild-type mice were not significantly different (P 5 0.086, 2-tailed t-test, Fig. 5b ). Together, these data demonstrate a clinically significant correction of the coagulation defect in haemophilia B, via direct in vivo delivery of ZFNs to mediate permanent correction of the genome in mouse hepatocytes.
To begin to evaluate the specificity of this approach, we used a method based on the systematic evolution of ligands by exponential enrichment (SELEX) 22 to identify the top 20 potential off-target sites for the F9 ZFNs in the mouse genome. Cel-I assays performed at each of these sites were unable to detect cleavage in 19 out of 20 (lower limit of detection 1%). At the twentieth site, located in an intergenic region at mouse chromosome 9qE3.1, we detected cleavage at a tenth the frequency seen at the F9 target site ( Supplementary Fig. 9 ). Thus, the specificity of the hF9 ZFNs is comparable to CCR5-specific ZFNs, by this analysis 22 .
To investigate the specificity of the ZFN approach further, we used ligation-mediated PCR and 454 pyrosequencing to detect sites of AAV vector integration genome-wide 24 . A comparison of ZFN 1 donor and mock 1 donor mice revealed similar distributions of AAV integration sites across the mouse genome ( Supplementary Fig. 10 ); this integration site distribution was consistent with previously reported data showing that genes 24, 25 , but not oncogenes, were favoured as integration sites. We next validated the prediction from in vitro studies 26 that a ZFN-induced DSB would capture the AAV vector itself, by employing a direct PCR approach using primers that anneal to the hF9mut locus and the AAV inverted terminal repeat (ITR) (Supplementary Fig. 11 ). This assay confirmed AAV integration at the ZFN target site in ZFN 1 donor mice but not in mock 1 donor mice. Finally, a pre-clinical evaluation of toxicity in injected and control mice showed no effects on growth or weight gain in either hF9mut or wild-type mice (n 5 43) over 8 months of observation (data not shown), and no changes in liver function tests at 4, 29 and 32 weeks after injection ( Supplementary Fig. 12 ), indicating that the treatment was well tolerated.
Studies showing that ZFNs can mediate gene correction efficiently through the introduction of site-specific DSBs, and can induce HDR in cultured cells, have provided important proof-of-concept results for the clinical application of engineered nucleases for diseases affecting cells that can be removed and returned to the patient. However, the necessity to isolate and manipulate cells ex vivo limits the application of this technology to a subset of genetic diseases. Our results show that AAV-mediated delivery of a donor template and ZFNs in vivo induces gene targeting, resulting in measurable circulating levels of factor IX. This therapeutic strategy is sufficient to restore haemostasis in a mouse model of haemophilia B, thus demonstrating genome editing in an animal model of a disease. Clinical translation of these results will require optimization of correction efficiency and a thorough analysis of off-target effects in the human genome, an issue that we have begun to monitor. Together, these data show that AAV-mediated delivery of ZFNs and a donor template gives rise to persistent and clinically meaningful levels of genome editing in vivo, and thus can be an effective strategy for targeted gene disruption or in situ correction of genetic disease in vivo.
METHODS SUMMARY
Zinc finger nucleases targeting the hF9 gene were designed and validated as described in Methods. ZFN expression, donor template and AAV-vector-production plasmids were constructed using standard molecular biology techniques. AAV vectors were produced through triple transfection of HEK 293T cells. K-562, Hep3B and HEK 293T cells were cultured and transfected using standard techniques. hF9mut mice were created by targeted transgenesis as described in Methods. Mouse injections, plasma collection and surgical procedures were approved by the Children's Hospital of Philadelphia institutional animal care and use committee, and performed as described in Methods. The Cel-I assay, target-site sequencing, restriction-fragment length polymorphism (RFLP) knock-in assay, targeting assay, human factor IX enzyme-linked immunosorbent assay (ELISA), aPTT, liver function tests, SELEX, ligation-mediated PCR and 454 sequencing were all performed as described in Methods.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. of haemophilia B. a, Levels of human factor IX in plasma of hF9mut/HB mice after intraperitoneal injection at day 2 of life with either 5 3 10 10 v.g. AAV8-ZFN alone (n 5 10 before PHx, n 5 1 after PHx), 5 3 10 10 v.g. AAV8-ZFN and 2.5 3 10 11 v.g. AAV8-donor (n 5 9 before PHx, n 5 5 after PHx), or 5 3 10 10 v.g. AAV8-mock and 2.5 3 10 11 v.g. AAV8-donor (n 5 9 before PHx, n 5 3 after PHx). Plasma levels of human factor IX were assayed by ELISA. Error bars denote s.e.m. b, Test of clot formation by aPTT at week 14 of life in mice that had received intraperitoneal injection at day 2 of life with 5 3 10 10 v.g. AAV8-ZFN and 2.5 3 10 11 v.g. AAV8-donor (n 5 5) or 5 3 10 10 v.g. AAV8-mock and 2.5 3 10 11 v.g. AAV8-donor (n 5 3). The aPTTs of wild-type (WT, n 5 5) and haemophilia B (HB, n 5 12) mice are shown for comparison. P-values are from 2-tailed Student's t-test of WT versus ZFN 1 donor, ZFN 1 donor versus mock 1 donor and mock 1 donor versus HB. Error bars denote s.e.m.
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METHODS ZFN reagents. ZFNs targeting the hF9 gene were designed by modular assembly using an archive of zinc finger proteins, as previously described 2 . The full amino acid sequences of the F9 ZFN pair are in Supplementary Fig. 1 . The ZFN expression vector that was used in vitro was assembled as previously described 27 . The F9 ZFN AAV production plasmid was constructed by transferring the coding sequence into pRS115, a vector containing the AAV2 ITRs. ZFN expression was under the control of the ApoE enhancer and ha 1 AT promoter from the previously described pAAV-hFIX16 plasmid 17 . Targeting vectors. The NheI RFLP donor plasmid was constructed by amplifying 1-kb regions flanking the ZFN cleavage site from K-562-cell genomic DNA. A short sequence containing the NheI restriction site was subsequently introduced between the left and right arms of homology, as described in ref. 16 . The NotI RFLP donor plasmid was constructed by amplifying the left (1 kb) and right (0.6 kb) arms of homology flanking the ZFN cleavage site from hF9mut mouse genomic DNA and cloning these into the production plasmid that contains the AAV2 ITRs, pRS165. A short sequence containing the NotI restriction site was subsequently introduced between the left and right arms of homology, as previously described 16 . The targeting vector used in vivo was built by cloning a cassette containing the splice acceptor, the coding sequence of exons 2-8 and the bovine growth hormone polyA signal from the pAAV-hFIX16 plasmid 20 into the NotI RFLP donor plasmid. Cell culture and transfection. K-562 cells (ATCC) were maintained at 37 uC under 5% CO 2 in RPMI medium supplemented with 10% FBS, and were transfected using the 96-well Nucleofector kit SF (Lonza) as per the manufacturer's recommendations. Hep3B cells (ATCC) were maintained at 37 uC under 5% CO 2 in DMEM medium supplemented with 10% FBS, and were transfected using the 96-well Nucleofector kit SE (Lonza). HEK 293T cells (ATCC) were maintained at 37 uC under 5% CO 2 in DMEM medium supplemented with 10% FBS, and were transfected using the 96-well Nucleofector kit SF (Lonza). Lentiviral vector for stable transduction of the hF9mut mini-gene into HEK 293T cells was made using the ViraPower HiPerform lentiviral expression system (Invitrogen). Surveyor nuclease (Cel-I) assay and target-site sequencing. Genomic DNA from K-562 and Hep3B cells was extracted using the QuickExtract DNA extraction solution (Epicentre Biotechnologies). ZFN target loci were amplified by PCR (30 cycles, 60 uC annealing and 30 s elongation at 68 uC) using the hF9cel1 forward primer (TCGGTGAGTGATTTGCTGAG) and hF9cel1 reverse primer (AACCT CTCACCTGGCCTCAT). Genomic DNA from mouse liver was isolated using the MasterPure complete DNA purification kit (Epicentre Biotechnologies). Primers for Cel-I of the hF9mut construct were hF9mut-cel1 forward (CTAGTAGCT GACAGTACC) and hF9mut-cel1 reverse (GAAGAACAGAAGCCTAATTA TG). The locus was amplified for 30 cycles (50 uC annealing and 30 s elongation at 68 uC). The assays were carried out as described previously 22 . For target-site sequencing, amplicons were cloned into the pCR-TOPO vector (Invitrogen) and sequenced using the primers M13forward (GTAAAACGACGGCCAGTG) and M13reverse (GGAAACAGCTATGACCATG). RFLP knock-in and targeting assays. Genomic DNA was extracted from K-562 and Hep3B cells using QuickExtract DNA extraction solution (Epicentre Biotechnologies). Genomic DNA from mouse liver was isolated using the MasterPure complete DNA purification kit (Epicentre Biotechnologies). The hF9 locus was amplified by 25 cycles of PCR (3 min extension at 68 uC and 30 s annealing at 55 uC) in the presence of radiolabelled dNTPs, using the hF9-TI forward (GGCCTTATTTACACAAAAAGTCTG) and hF9-TI reverse (TTTGC TCTAACTCCTGTTATCCATC) primers. The PCR products were then purified with G50 columns, digested with NheI, resolved by 5% PAGE and autoradiographed. RFLP assays in HEK 293T cells transduced with the hF9mut mini-gene were genotyped as described above, using the P1 (ACGGTATCGATAAG CTTGATATCGAATTCTAG) and P2 (CACTGATCTCCATCAACATACTGC) primers, and the PCR products (25 cycles, 63 uC annealing and 2 min extension at 65 uC) were digested with NotI. To quantify the targeting of the 'splice acceptorexons 2-8 coding sequence -bovine growth hormone polyA signal' cassette, gDNA was amplified using the P1 and P3 (GAATAATTCTTTAGTTTTA GCAA) or the P1 and P2 primer pairs by 25 cycles of PCR (4 min extension time at 65 uC and 30 s annealing at 48 uC) in the presence of radiolabelled dNTPs. The PCR products were then purified with G50 columns, resolved by 5% PAGE and autoradiographed. All PCR reactions were performed using Accuprime Taq HiFi (Invitrogen). To capture the NHEJ-mediated insertion of the AAV vector at the hF9 ZFN cut-site, gDNA was amplified using P1 and P4 (AGGAACC CCTAGTGATGGAG) primers by 25 cycles of PCR (80 s extension time at 65 uC) in the presence of radiolabelled dNTPs. The PCR reactions were performed using Phusion High-fidelity DNA polymerase (New England BioLabs) in conjunction with GC Buffer and 3% dimethylsulphoxide. The PCR products were then purified with G50 columns, resolved by 5% PAGE and autoradiographed.
hF9mut mouse generation. The hF9mut construct (sequence provided in Supplementary Fig. 14) was constructed by gene synthesis (Genscript) and ligated into the pUC57 plasmid. The hF9mut construct was then excised and ligated into a proprietary plasmid between FLP recombinase sites compatible for recombinasemediated cassette exchange (RCME) (Taconic-Artemis), to create the hF9mut KI plasmid. The hF9mut KI plasmid and a FLP recombinase expression plasmid (Taconic-Artemis) were transfected into B6S6F1 embryonic stem (ES) cells (Taconic-Artemis) containing FLP recombinase sites compatible for RCME at the ROSA26 locus 20 . Correctly targeted B6S6F1-hF9mut ES cell clones were identified by Southern blot and injected into B6D2F1 blastocysts. Pure ES-cell-derived B6S6F1-hF9mut mice (G0) were delivered by natural birth and chimaeric pups were backcrossed with C57BL/6J mice (Jackson Laboratories) for 5 generations (for in vivo cleavage experiments) or 7-10 generations (for in vivo gene targeting experiments). hF9mut mice were genotyped using primers hF9mut Oligo 1 (ACTGTCCTCTCATGCGTTGG), hF9mut Oligo 2 (GATGTTGGAGGTGGCA TGG), wtROSA Oligo 1 (CATGTCTTTAATCTACCTCGATGG), wtROSA Oligo 2 (CTCCCTCGTGATCTGCAACTCC), mFVIII Oligo1 (GAGCAAATTC CTGTACTGAC) and mFVIII Oligo 2 (TGCAAGGCCTGGGCTTATTT). HB mice have been backcrossed with C57BL/6J mice (Jackson Laboratories) for .10 generations and were genotyped using previously described primers 20 . C57BL/6J mice (Jackson Laboratories) were used for hF9mut-negative gene targeting experiments. AAV vector production. AAV serotype 8 vectors were produced by triple transfection methods into HEK 293T cells, and subsequent CsCl density-gradient purification, as previously described 28 . Animal experiments. AAV vector was diluted to 200 ml with PBS before tail-vein injection. AAV vector was diluted to 20 ml with PBS before neonatal intraperitoneal injection. Plasma for human factor IX ELISA was obtained by retro-orbital bleeding into heparinized capillary tubes. Plasma for aPTT was obtained by tail bleeding, 9:1 into 3.8% sodium citrate. Partial hepatectomies were performed as previously described 29 . Tissue for nucleic acid analysis was immediately frozen on dry ice after necropsy. All animal procedures were approved by the institutional animal care and use committee of the Children's Hospital of Philadelphia. SELEX. In silico identification of potential off-target ZFN cleavage sites was performed by identifying homologous regions within the genome, as previously described 22 . LM-PCR and 454 sequencing. AAV-donor integration junctions were cloned and sequenced as previously described 24 . In brief, genomic DNA from mouse liver was isolated using the MasterPure complete DNA purification kit (Epicentre Biotechnologies). 1 mg of DNA was digested with MseI (New England Biolabs) and 1 mg of DNA was digested with CviQ1 (New England Biolabs) for 16 h at 37 uC. These two enzymes were chosen for their ideal proximity to the target site. Digested DNA was purified using a PCR purification kit (Qiagen), then a previously described double-stranded linker 24 was ligated to digested DNA ends using T4 DNA ligase (New England Biolabs) for 16 h at 16 uC. Integration junctions were then PCR-amplified using an adaptor primer (GTAATACGACTCACTATAG GGC) and a stuffer primer (CTCCAACTCCTAATCTCAGGTGATCTACCC). PCR products were diluted 1:200 in TE buffer and integration junctions were PCR-amplified again, using a second adaptor primer (CGTATCGCCTCCCTC GCGCCATCAGnnnnnnnnnnAGGGCTCCGCTTAAGGGAC, where nnnnnnnnnn is a sample-specific barcode) and a second stuffer primer (CTATGCGCCTTGCC AGCCCGCTCAGnnnnnnnnnnACCTTGGCCTCCCAAATTGCTGGG, where nnnnnnnnnn is a sample-specific barcode). Amplified integration junctions were then sequenced using a Genome Sequencer FLX pyrosequencer (Roche/454). Integration-site analysis. Pyrosequencing reads were first decoded using DNA barcodes, separating sequence reads by mouse. Reads were then aligned against the linker and stuffer primers using the Crossmatch program (-minmatch 8 -penalty 22 -minscore 6). Reads matching one or the other primer were then aligned using BLAT against three target sequences: the stuffer, the AAV-ITR and the hF9mut construct. BLAT parameters were optimized to find repetitive and/or short-sequence hits against each target sequence (-stepSize 5 3, -tileSize 5 8, -repMatch 5 16384, -minScore 5 5, -minIdentity 5 50, -oneOff 5 1). Additionally, BLAT fastMap option was included for alignment against the stuffer and the hF9mut construct. BLAT hits originating from the ITR were processed as previously described 24 . BLAT hits originating from the stuffer and the hF9mut construct were identified by requiring a unique high-scoring match requiring at least 90% sequence identity with a #5-base-pair gap. All the BLAT hits from each of the three target sequences were consolidated and ordered by their location within each read. Reads that had stuffer and/or linker with ITR but no hF9mut construct were segregated and aligned using BLAT against the mouse genome. BLAT hits in the mouse genome were scored using the same criteria as described above and were required not to overlap with hits originating from stuffer, ITR and linker. A master table of all the reads and their respective target hits was constructed to manage the RESEARCH LETTER
